$NPCE
Neuropace Inc Stock $npce

$npce Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000152828724000020 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$21.06M
YoY Change		28.2%
Cost Of Revenue		$5.640M
YoY Change		34.48%
Gross Profit		$15.42M
YoY Change		26.05%
Gross Profit Margin		73.22%
Selling, General & Admin		$13.91M
YoY Change		3.89%
% of Gross Profit		90.2%
Research & Development		$5.754M
YoY Change		20.0%
% of Gross Profit		37.32%
Depreciation & Amortization		$100.0K
YoY Change		0.0%
% of Gross Profit		0.65%
Operating Expenses		$19.66M
YoY Change		8.14%
Operating Profit		-$4.243M
YoY Change		-28.69%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$219.0K
YoY Change		90.43%
Pretax Income
YoY Change
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$5.452M
YoY Change		-24.87%
Net Earnings / Revenue		-25.89%
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share		-$0.19
COMMON SHARES
Basic Shares Outstanding	29.85M shares	29.20M shares
Diluted Shares Outstanding		29.44M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$15.42M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$12.08M
Prepaid Expenses
Receivables		$11.56M
Other Receivables
Total Short-Term Assets		$82.59M
YoY Change		-1.65%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.041M
YoY Change		9.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$15.00K
YoY Change		0.0%
Total Long-Term Assets		$13.71M
YoY Change		-10.53%
TOTAL ASSETS
Total Short-Term Assets		$82.59M
Total Long-Term Assets		$13.71M
Total Assets		$96.30M
YoY Change		-3.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.160M
YoY Change		78.96%
Accrued Expenses		$10.07M
YoY Change		0.36%
Deferred Revenue		$700.0K
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$14.78M
YoY Change		15.34%
LONG-TERM LIABILITIES
Long-Term Debt		$59.27M
YoY Change		6.04%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$59.27M
YoY Change		6.04%
TOTAL LIABILITIES
Total Short-Term Liabilities		$14.78M
Total Long-Term Liabilities		$59.27M
Total Liabilities		$86.48M
YoY Change		4.27%
SHAREHOLDERS EQUITY
Retained Earnings		-$525.7M
YoY Change		5.65%
Common Stock		$30.00K
YoY Change		15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$9.823M
YoY Change
Total Liabilities & Shareholders Equity		$96.30M
YoY Change		-3.02%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$5.452M
YoY Change		-24.87%
Depreciation, Depletion And Amortization		$100.0K
YoY Change		0.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	NEUROPACE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3550230
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 N. Bernardo Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
	dei	City Area Code CityAreaCode	650
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29848101	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15418000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18058000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	41412000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	48396000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11561000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12314000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	12084000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11214000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2116000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2737000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	82591000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	92719000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1041000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1003000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12246000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13405000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	288000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	387000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2024Q3	us-gaap	Assets Assets	96303000	usd
CY2023Q4	us-gaap	Assets Assets	107651000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2160000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2332000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10072000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11180000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1800000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1627000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29777966	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29777966	shares
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4194000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15543000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12832000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	15420000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	12233000	usd
	us-gaap	Gross Profit GrossProfit	42897000	usd
	us-gaap	Gross Profit GrossProfit	34577000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5754000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4795000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17603000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15401000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13909000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001528287
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Local Phone Number LocalPhoneNumber	237-2700
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	NPCE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-525700000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-503809000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	9823000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20654000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96303000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107651000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21060000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16427000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	58440000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47409000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5640000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13388000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	43312000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41299000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	19663000	usd
	us-gaap	Operating Expenses OperatingExpenses	56700000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5950000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18018000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22123000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	754000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	769000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2343000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2228000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	219000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	115000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	390000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-580000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5452000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21891000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26756000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34777000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9839000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Term ResearchAndDevelopmentArrangementWithFederalGovernmentTerm	P5Y
CY2021Q2	npce	Research And Development Arrangement With Federal Government Total Estimated Cost ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost	9300000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Estimated Cost For Subawards ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards	5500000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Approved Funding Year1 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1	800000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Approved Funding Subawards Year1 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1	400000	usd
CY2022Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2	2600000	usd
CY2022Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2	1600000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29444625	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Operating Expenses OperatingExpenses	60915000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4243000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1090000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14781000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16229000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	59266000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	56954000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12433000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13814000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	86480000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	86997000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	535493000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	524435000	usd
	dei	Entity File Number EntityFileNumber	001-40337
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	18183000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2182000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2191000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6606000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6281000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28863120	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28863120	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25532415	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25532415	shares
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	749000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27823465	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27823465	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7257000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29444625	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29444625	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26017329	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26017329	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20654000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8925000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	721000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	649000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2540000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14341000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-7514000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	53000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	528000	usd
CY2024Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	72000	usd
CY2024Q2	npce	Adjustments To Additional Paid In Capital Change In Early Exercise Liability AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability	-1000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2548000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9885000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5452000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	189000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2833000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	68000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2591000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	9823000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10375000	usd
CY2023Q1	npce	Oci Unrealized Loss Adjustment For Short Term Investment OCIUnrealizedLossAdjustmentForShortTermInvestment	1108000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	146000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2125000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27490000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-9124000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	240000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	41000	usd
CY2023Q2	npce	Adjustments To Additional Paid In Capital Change In Early Exercise Liability AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability	-1000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2655000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	21226000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7257000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	35000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2421000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	16363000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21891000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26756000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7679000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7201000	usd
	us-gaap	Depreciation Depreciation	159000	usd
	us-gaap	Depreciation Depreciation	132000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	179000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	207000	usd
	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	743000	usd
	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	775000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1389000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1994000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1159000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1064000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	315000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-580000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	196000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	132000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-753000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3798000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1066000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	179000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-621000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1530000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-102000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-815000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1108000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2623000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-341000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1207000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1050000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13152000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16360000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	267000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7300000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	19700000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7033000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19559000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1336000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	254000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	789000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	222000	usd
	npce	Proceeds From Issuance Of Common Stock Net Of Sales Commissions And Offering Costs ProceedsFromIssuanceOfCommonStockNetOfSalesCommissionsAndOfferingCosts	2932000	usd
	npce	Proceeds From Issuance Of Common Stock Net Of Sales Commissions And Offering Costs ProceedsFromIssuanceOfCommonStockNetOfSalesCommissionsAndOfferingCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	119000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3479000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-87000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2640000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3112000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18180000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6727000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15540000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15418000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9717000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15540000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9839000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4294000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3305000	usd
	npce	Deferred Offering Costs Offset Against Additional Paid In Capital DeferredOfferingCostsOffsetAgainstAdditionalPaidInCapital	99000	usd
	npce	Deferred Offering Costs Offset Against Additional Paid In Capital DeferredOfferingCostsOffsetAgainstAdditionalPaidInCapital	0	usd
	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	-1000	usd
	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	-1000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-525700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16400000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56800000	usd
	npce	Debt Instrument Covenant Minimum Annual Net Revenue DebtInstrumentCovenantMinimumAnnualNetRevenue	70000000.0	usd
CY2024Q3	npce	Debt Instrument Covenant Minimum Cash And Cash Equivalents Required After Completion Of Ipo DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO	5000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three and nine months ended September 30, 2024 and 2023, there were no customers that represented 10% or more of revenue. As of September 30, 2024 and December 31, 2023, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of comprehensive epilepsy centers, or CECs, and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	700000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1100000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1900000	usd
CY2023Q2	npce	Research And Development Arrangement With Federal Government Approval For Funding Year3 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear3	3000000	usd
CY2023Q2	npce	Research And Development Arrangement With Federal Government Approval For Funding Subawards Year3 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear3	1500000	usd
CY2024Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Year4 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear4	1700000	usd
CY2024Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Subawards Year4 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear4	1000000	usd
CY2024Q3	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	400000	usd
CY2023Q3	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	500000	usd
	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	1400000	usd
	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	1000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	14968000	usd
CY2024Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	41412000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	56380000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16125000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	48396000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	64521000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2024Q3	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	200000	usd
CY2023Q3	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	100000	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	300000	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	700000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	400000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	200000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4260000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4090000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1492000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	627000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6332000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6497000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	12084000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11214000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8967000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8770000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7926000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7767000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1041000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1003000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	200000	usd
	us-gaap	Depreciation Depreciation	100000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7635000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9655000	usd
CY2024Q3	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	1478000	usd
CY2023Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	588000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	120000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	839000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	907000	usd
CY2024Q3	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	10072000	usd
CY2023Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	11180000	usd
CY2022Q3	npce	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	714000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2942000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3031000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3122000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3215000	usd
CY2024Q3	npce	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	5017000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18041000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3808000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	14233000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1800000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12433000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2100000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2100000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000	usd
CY2022Q3	npce	Distribution Agreement Initial Term DistributionAgreementInitialTerm	P3Y
CY2022Q3	npce	Distribution Agreement Renewal Term DistributionAgreementRenewalTerm	P1Y
CY2022Q3	npce	Distribution Agreement Period For Notice Of Non Renewal DistributionAgreementPeriodForNoticeOfNonRenewal	P180D
CY2022Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2400000	usd
CY2022Q3	npce	Purchase Obligation Minimum Increase Percentage In Next Two Years PurchaseObligationMinimumIncreasePercentageInNextTwoYears	0.10
CY2022Q3	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P2Y
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q1	npce	Debt Instrument Principal Payment Number Of Installment DebtInstrumentPrincipalPaymentNumberOfInstallment	1	installment
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6861480	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6733868	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2588765	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	487654	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.33
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	519314	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	142689	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.67
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2414416	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.12
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M13D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1548358	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.67
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2414416	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.12
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y4M13D
CY2024Q3	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	0	shares
CY2023Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	30211	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2021Q2	npce	Employee Stock Purchase Plan Length Of Offering Period EmployeeStockPurchasePlanLengthOfOfferingPeriod	P6M
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2591000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2421000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7679000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7201000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2591000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2421000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7679000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7201000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	16900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5452000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7257000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21891000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26756000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29444625	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26017329	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26017329	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28863120	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28863120	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25532415	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25532415	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4168792	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5664776	shares
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001528287-24-000020-index-headers.html	Edgar Link	pending
0001528287-24-000020-index.html	Edgar Link	pending
0001528287-24-000020.txt	Edgar Link	pending
0001528287-24-000020-xbrl.zip	Edgar Link	pending
exhibit311certificationsq3.htm	Edgar Link	pending
exhibit312certificationsq3.htm	Edgar Link	pending
exhibit321certificationsq3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
npce-20240930.htm	Edgar Link	pending
npce-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
npce-20240930_cal.xml	Edgar Link	unprocessable
npce-20240930_def.xml	Edgar Link	unprocessable
npce-20240930_lab.xml	Edgar Link	unprocessable
npce-20240930_pre.xml	Edgar Link	unprocessable
npce-20240930_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NPCE
Neuropace Inc Stock $npce

2024 Q4 Form 10-Q Financial Statement

#000152828724000020 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE Neuropace Inc Stock $npce

2024 Q4 Form 10-Q Financial Statement

#000152828724000020 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE
Neuropace Inc Stock $npce